株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の核医学診断市場 (SPECT・PET) :分析と予測

Nuclear Medicine Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 353811
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.95円で換算しております。
世界の核医学診断市場 (SPECT・PET) :分析と予測 Nuclear Medicine Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年02月01日 ページ情報: 英文 120 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

世界の核医学診断市場は、2019年までに176億米ドルに達し、2014年~2019年のCAGR (複合年間成長率) で12.29%の成長が予測されています。

当レポートでは、世界の核医学診断市場について調査分析し、市場の概要、市場促進要因・抑制要因・機会、セグメント別の市場分析、競合情勢、主要企業など、体系的な情報を提供しています。

目次

  • イントロダクション
  • 調査手法
  • エグゼクティブサマリー
  • 主な推論
  • 市場概要と産業動向
  • 現在の市場シナリオ
  • 応用
  • 技術概要
  • 新しい発展
  • 産業バリューチェーン分析
  • Porterのファイブフォース分析
  • 促進要因、抑制要因、機会、課題の分析
  • 市場促進要因
  • 市場抑制要因
  • 市場の課題
  • 市場区分
  • 製品の種類別
  • SPECT
  • PET
  • その他
  • 市場区分 (地域別) :地域別のシェアと予測
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・北アフリカ
  • 南米
  • 競合情勢
  • M&A分析
  • 新製品の発売
  • 契約、提携、パートナーシップ
  • 主要ベンダー分析
  • Mallinckrodt
  • Lantheus Medical Imaging
  • IBA Group
  • Triad Isotope
  • Siemens Healthcare
  • NTP Radioisotopes
  • Bracco Pharma
  • Cambridge Isotope Laboratories, Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Nordion, Inc.
  • 太陽日酸
  • 富士フイルムホールディングス
  • Eczacibasi-Monrol
  • Isotec, Inc.
  • Petnet Solutions, Inc.
  • 投資機会の見通し
  • 市場の将来見通し
目次
Product Code: 53628

Nuclear medicine has a huge potential in treating cancer and cardiac diseases. The International Agency for Research on Cancer (IARC) predicts that, by 2030, the global burden is expected to increase to 21.7 million new cancer cases and 13 million cancer deaths, due to the growth and aging of the population, apart from other factors, such as smoking, poor diet, physical inactivity, and fewer childbirths. Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Nuclear medicine plays an important role in the diagnosis and management of patients with chronic diseases, which is a key growth factor for the market studied.

Key Market Trends

Technetium-99m Segment is Expected to Show Better Growth in the Forecast Years

Based on Type, it is segmented into SPECT and PET. The SPECT is further sub-segmented into Technetium-99m, Thallium-201, Iodine-123, Gallium-67, and Others. Technetium 99m is considered as the most widely used single isotope in several diagnostic procedures. Globally, approximately 30 million procedures are carried out every year, with technetium 99m (TC-99m), and this is expected to grow rapidly in the coming years. It is used in SPECT imaging, cardiac ventriculography, brain imaging, bone scans, and 3D scanning techniques. The growth and widespread applications of diagnostic nuclear medicine have been mainly driven by the easy availability of TC-99m. Furthermore, the increasing burden of non-communicable and chronic diseases, such as cancer and cardiac disorders, and the advancement in imaging technologies, such as SPECT/CT are fueling the demand for Technetium-99m in various applications.

North America Dominates the Nuclear Medicine Diagnostics Market

North America region is among the major contributor in this market due to the advancements in technology, and introduction of new radiopharmaceuticals for diagnosis. According to the National Oncology PET Registry, about 84% of more than 1,600 PET facilities in the United States have PET/CT systems. Thus, the emergence of molecular imaging, with new radiopharmaceuticals and new technologies, is likely to result in continued growth in the coming decades. Moreover, rising disease burden is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The global players in the nuclear medicine diagnostics market are - Bayer AG, Bracco SpA, Cardinal Health Inc., Curium SAS, GE Healthcare, Lantheus Holdings, Inc., NTP Radioisotopes SOC Ltd, and Sotera Health (Nordion, inc.).

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Cancer and Cardiac Disorders
    • 4.2.2 Increasing SPECT and PET Applications
    • 4.2.3 Widening Applications of Nuclear Medicine
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement and Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 SPECT
      • 5.1.1.1 Technetium-99m (TC-99m)
      • 5.1.1.2 Thallium-201 (TL-201)
      • 5.1.1.3 Iodine-123 (I-123)
      • 5.1.1.4 Gallium-67 (Ga-67)
      • 5.1.1.5 Others
    • 5.1.2 PET
      • 5.1.2.1 Fluorine-18
      • 5.1.2.2 Rubidium-82 (RB-82)
      • 5.1.2.3 Others
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology
    • 5.2.3 Neurology
    • 5.2.4 Thyroid
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Bracco SpA
    • 6.1.3 Cardinal Health Inc.
    • 6.1.4 Curium SAS
    • 6.1.5 GE Healthcare
    • 6.1.6 Lantheus Holdings, Inc.
    • 6.1.7 NTP Radioisotopes SOC Ltd
    • 6.1.8 Sotera Health (Nordion, inc.)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS